Robert W. Baird Upgrades Henry Schein (NASDAQ:HSIC) to “Outperform”

Henry Schein (NASDAQ:HSIC) was upgraded by research analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report released on Monday, MarketBeat Ratings reports. The firm currently has a $92.00 target price on the stock, up from their previous target price of $81.00. Robert W. Baird’s price target points to a potential upside of 31.45% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Barrington Research reaffirmed an “outperform” rating and set a $92.00 price objective on shares of Henry Schein in a research report on Friday, July 5th. Evercore ISI reduced their price target on shares of Henry Schein from $75.00 to $72.00 and set an “in-line” rating for the company in a report on Tuesday, July 9th. UBS Group dropped their price objective on shares of Henry Schein from $82.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, May 8th. Finally, Piper Sandler reissued an “overweight” rating and set a $86.00 price objective on shares of Henry Schein in a research report on Friday, June 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Henry Schein Trading Down 1.4 %

NASDAQ HSIC opened at $69.99 on Monday. The firm has a market capitalization of $8.96 billion, a PE ratio of 23.65, a price-to-earnings-growth ratio of 1.75 and a beta of 0.87. The business’s 50-day moving average price is $68.28 and its two-hundred day moving average price is $71.92. The company has a current ratio of 1.75, a quick ratio of 1.02 and a debt-to-equity ratio of 0.47. Henry Schein has a 12 month low of $60.01 and a 12 month high of $82.63.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 7th. The company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.01 by $0.09. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.21 billion. During the same period in the prior year, the business posted $1.21 earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. On average, analysts expect that Henry Schein will post 5.16 EPS for the current year.

Institutional Investors Weigh In On Henry Schein

A number of hedge funds have recently made changes to their positions in HSIC. Beach Investment Counsel Inc. PA purchased a new position in Henry Schein in the second quarter valued at about $37,000. McGlone Suttner Wealth Management Inc. bought a new position in Henry Schein during the fourth quarter valued at $39,000. Blue Trust Inc. increased its position in Henry Schein by 104.2% in the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock worth $60,000 after buying an additional 475 shares during the last quarter. Mather Group LLC. increased its position in Henry Schein by 16.8% in the second quarter. Mather Group LLC. now owns 1,502 shares of the company’s stock worth $96,000 after buying an additional 216 shares during the last quarter. Finally, Palisade Asset Management LLC bought a new stake in shares of Henry Schein in the first quarter valued at $113,000. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.